Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prevention of platelet alloimmunization.

S J Slichter

    Progress in Clinical and Biological Research
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Preventing platelet alloimmunization involves using leukocyte-poor products or single-donor platelets. Newer strategies focus on inhibiting T cells and removing donor antigens to improve transfusion outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.

    Vox sanguinis·2016
    Same author

    Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model.

    Vox sanguinis·2016
    Same author

    Extended storage of autologous apheresis platelets in plasma.

    Vox sanguinis·2013
    Same author

    Platelet transfusion: future directions.

    Vox sanguinis·2004
    Same author

    Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

    Blood·2001
    Same author

    Universal WBC reduction.

    Transfusion·2000

    Area of Science:

    • Immunology
    • Transfusion Medicine
    • Hematology

    Background:

    • Platelet alloimmunization is a significant complication in patients requiring frequent transfusions.
    • Current methods like leukocyte-poor platelets and single-donor products have limitations in efficacy and accessibility.
    • Aplastic anemia patients may respond less effectively to existing strategies.

    Purpose of the Study:

    • To review established and explore novel strategies for delaying or preventing platelet alloimmunization.
    • To discuss the potential of new immunomodulatory and antigen-removal techniques.

    Main Methods:

    • Review of transfusion studies in patients and animal models.
    • Discussion of established methods: leukocyte-poor platelets and single-donor pheresis products.

    Related Experiment Videos

  • Exploration of novel approaches including immunosuppression (Cyclosporin A), antigen-presenting cell (APC) elimination, and antigen removal from platelets.

    • Main Results:

    • Established methods have practical limitations and may be less effective in certain patient populations.
    • Cyclosporin A effectively inhibits T cells, a key component of immune recognition.
    • Eliminating APCs and removing HLA antigens from platelets are promising strategies.
    • Platelets lacking Class II MHC antigens may induce tolerance.

    Conclusions:

    • Novel strategies targeting T cell inhibition and antigen removal offer significant potential for preventing platelet alloimmunization.
    • Further research into "pure" platelet transfusions could revolutionize transfusion therapy by inducing tolerance.